The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Lastacaft Solution of AbbVie Inc. Alcaftadine Ophthalmic Solution is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander. Alembic has a cumulative total of 216 ANDA approvals (189 final approvals and 27 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of pharmaceutical products, i.e. formulations and active pharmaceutical ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024. The scrip fell 1.03% to currently trade at Rs 1229.35 on the BSE. Powered by Capital Market - Live

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Lamotrigine Extended-Release Tablets USP, 200 mg, 250 mg, and 300 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Lamictal XR Extended-Release Tablets, 200 mg, 250 mg, and 300 mg, of GlaxoSmithKline LLC (GSK). Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. Also indicated for conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug. Lamotrigine Extended-Release Tablets USP, 200 mg, 250 mg, and 300 mg have an estimated market size of US$ 163 million for twelve months ending June 2024 according to IQVIA. Alembic has a cumulative total of 216 ANDA approvals (188 final approvals and 28 tentative approvals) from USFDA.Powered by Capital Market - Live

Stocks t watch: Alembic Pharmaceuticals' oral solid formulation facility (F-1) located in Panelav, Gujarat received establishment inspection report (EIR) from United States Food and Drug Administration (USFDA), which was inspected by USFDA from 17 July to 26 July 2024. Bajel Projects had successfully entered the emerging data centre segment by securing its first order from an upcoming data centre service provider. The order involves the design and construction of a 220/33kV gas-insulated switchgear (GIS) substation and transmission line extension for a colocation data centre in Navi Mumbai, Maharashtra. Zydus Lifesciences received final approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Capsules, 40 mg. Lupin's Pithampur facility in Madhya Pradesh, which includes the unit-1 API and finished product manufacturing site, has completed the U.S. Food and Drug Administration (USFDA) inspection with 3 observations. Adani Enterprises' unit April Moon will acquire a 74% stake in Cococart Ventures for Rs 200 crore. Adani Energy Solutions has signed a business transfer agreement with its subsidiary, North Maharashtra Power to carve out the Adani Dahanu Thermal Power Station. Adani Electricity Mumbai is a subsidiary of the company. IndusInd Bank's board has approved the re-apppointment of Sumant Kathpali as managing director & chief executive officer (CEO) for a term of three years, effective from 24 March 2025.This re-appointment is subject to approval by the reserve bank of India and bank's shareholder. Biocon's API facility (Site 2) in Bengaluru was inspected by US Food and Drug Administration (USFDA), from 23 September to 27 September 2024 ended with four observations.Powered by Capital Market - Live

Earlier, on 26 July 2024, the pharmaceutical company informed that it had successfully completed the USFDA inspection of its Oral Solid Formulation Facility (F-I) in Panelav. This scheduled GMP inspection was completed without any form 483 observations. The inspection had been conducted from 17 July 2024 to 26 July 2024. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024. Shares of Alembic Pharma shed 0.27% to settle at Rs 1,192.65 on Friday 27 September 2024.Powered by Capital Market - Live

The said drug is therapeutically equivalent to the reference listed drug product (RLD), Invega extended-release tablets of Janssen Pharmaceuticals, Inc. Paliperidone extended-release tablets are used to treat the symptoms of psychotic disorders, including schizophrenia. it is also indicated for the treatment of schizoaffective disorder, both as a monotherapy and as an adjunct to mood stabilizers and antidepressants. Paliperidone extended-release tablets, have an estimated market size of $ 48 million for twelve months ending June 2024, according to IQVIA. Alembic has a cumulative total of 215 ANDA approvals (187 final approvals and 28 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024. The scrip shed 0.29% to Rs 1,192.45 on the BSE.Powered by Capital Market - Live

Alembic Pharmaceuticals has appointed Sudhakar Pandiyan as Head - Technical Operations (Sterile & Oncology), designated as Senior Management Personnel of the Company w.e.f. 16 September 2024. Powered by Capital Market - Live

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Albendazole Tablets USP, 200 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), LAlbenza Tablets, 200 mg, of Impax Laboratories, Inc. (Impax). Albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. It is also indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. Powered by Capital Market - Live

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam of Norvium Bioscience, LLC (Norvium). Betamethasone valerate foam is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. The company has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024.Powered by Capital Market - Live

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam of Norvium Bioscience, LLC (Norvium). Betamethasone valerate foam is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. The company has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024. The scrip slipped 1.50% to settle at Rs 1,100.55 on Friday, 23 August 2024. Powered by Capital Market - Live

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Betamethasone Valerate Foam, 0.12%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam, 0.12%, of Norvium Bioscience, LLC (Norvium). Betamethasone valerate foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. Refer label for a detailed indication. Alembic has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA.Powered by Capital Market - Live